Replies to post #301610 on Innovation Pharmaceuticals Inc (IPIX)

[TheDane]

These wildly overhyped predictions aren’t helping the cause. Let’s start at a dollar as a possibility. What you’re talking about is based on so many ifs and maybes with hypothetical suppositions As foundations it makes the predictions useless.

Get going, Leo! No more PRs unless you have something that doesn’t require a Forward Looking Statement advisory. Try this...

“IPIX, in collaboration with an unnamed RBL, has applied for a grant for the development of BrilAcidin for...etc., etc.

Did you or didn’t you?

[MinnieM]

507 total participants have been dosed with Brilacidin (aka PMX-30063) via IV in human clinical trials.
215 + 77 + 215 = 507

Polymedix had multiple trials for ABSSSI. The ph I was done in the EU and I don't have the link handy.

Here is their ph II with 215 participants. Drug listed as PMX-30063
https://clinicaltrials.gov/ct2/show/NCT01211470?term=polymedix&cond=ABSSSI&draw=2&rank=1

I found an old Polymedix pr that says a total of 77 subjects were treated in their ph I trial.
https://www.businesswire.com/news/home/20100928005299/en/PolyMedix-Initiates-Phase-2-Clinical-Trial-Antibiotic

PolyMedix has completed two Phase 1 clinical trials in which a combined total of 77 healthy subjects received PMX-30063. In those clinical trials, PMX-30063 was safely administered in single or multiple doses without serious adverse effects. The only drug-related reactions of clinical importance to date have been paresthesias (abnormal sensations of numbness and tingling), which were mild, transient, non-disabling, and resolved on their own.

Here's the study done by Innovation Pharmaceuticals, Inc. ( Cellceutix Corporation ) It had 215 participants for the ph 2b Brilacidin for ABSSSI
https://clinicaltrials.gov/ct2/show/NCT02052388?term=brilacidin&cond=ABSSSI&draw=2&rank=2

Rationale for using Brilacidin against covid19
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf

Btw, I don't like to even guess at valuations since too many variables exist.









Message in reply to:

Do we know the total headcount of patients that had taken Bril altogether? That's just safety profile of drug as to why they'll be testing Bril Phase II patients in CV19 patients?

Bril could be worth as much as a 10b tag price since its the flagship. Cv19 trials will help us get to $3b+ valuation. Maybe $5b cash upfront plus up to $5b in CVR? Ipix can throw in K for free!